

Non-GAAP Financial Measures and Reconciliations

We use various numerical measures in conference calls, investor meetings and other forums which are or may be considered "Non-GAAP financial measures" under Regulation G. We have provided below for your reference supplemental financial disclosure for these measures, including the most directly comparable GAAP measure and an associated reconciliation.

Kensey Nash Corporation Non-GAAP Financial Measures and Reconciliations For the Fiscal Year 2008 Quarter September 30, 2007 Endovascular Sales Reconciliation

	(Unaudited) Three Months Ended September 30, <u>2007</u>	(Unaudited) Three Months Ended June 30, <u>2007</u>	Sequential Quarter % Change
Endovascular sales, as reported	\$1,364,230	\$805,574	69%
<i>Adjustments:</i>			
Embolic protection sales credits	\$0	\$356,261	
Non-GAAP Endovascular sales as adjusted	\$1,364,230	\$1,161,835	17%

Note: To supplement our forecasted guidance presented in accordance with GAAP, Kensey Nash Corporation uses non-GAAP measures of as adjusted Endovascular sales, which are adjusted from our GAAP results to exclude certain expenses and credits. These non-GAAP adjustments are provided to enhance the user's overall understanding of our historical and current financial performance and our prospects for the future. We believe the non-GAAP guidance provides useful information to both management and investors by excluding certain expenses and credits that we believe are not indicative of our core operating results.

We have adjusted our GAAP results for embolic protection sales credits related to the discontinuance of our embolic protection platform. As previously announced, the Company has excluded the impact of sales credits offered to its customers for unused embolic protection product related to the Company's decision in June 2007 to discontinue the embolic protection platform, as set forth in the reconciliation.

These non-GAAP measures will provide investors and management with an alternative method for assessing Kensey Nash's operating results in a manner consistent with future presentation as a result of the discontinuance of our embolic protection platform. Further, these non-GAAP results are one of the primary indicators management uses for planning and forecasting in future periods. The presentation of this additional information should not be considered in isolation or as a substitute for results prepared in accordance with accounting principles generally accepted in the United States.